Insights from Pim1 structure for anti-cancer drug design

Expert Opinion on Drug Discovery

Volumn 7, Issue 12, 2012, Pages 1177-1192

  Ogawa, Naoko ^a   Yuki, Hitomi ^a   Tanaka, Akiko ^a  

^a RIKEN   (Japan)

Author keywords

Apoptosis; Cancer; Drug design; Leukemia; Proliferation; Serine threonine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 1208; BENZOTHIENOPYRIMIDINE DERIVATIVE; BETA CARBOLINE; BIM 1; CX 6258; HYDROXYBENZOFURAN DERIVATIVE I; HYDROXYBENZOFURAN DERIVATIVE II; K 00135; LY 2835219; MYRICETIN; PHENYLPYRIMIDINE DERIVATIVE; PLX K 031; PROTEIN KINASE PIM 1; QUINAZOLINE DERIVATIVE; SGI 1776; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING SITE; CELL CYCLE REGULATION; COMPLEX FORMATION; DRUG DESIGN; DRUG TARGETING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 84870230687     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.727394     Document Type: Review

References (98)

1. Cuypers HT, Selten G, Quint W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984;37:141-50 (Pubitemid 14079845)
2. van der Lugt NM, Domen J, Verhoeven E, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 protooncogene leads to compensatory activation of Pim-2. EMBO J 1995;14:2536-44
3. Feldman JD, Vician L, Crispino M, et al. KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998;273:16535-43 (Pubitemid 28311439)
4. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23-34. This review article discusses the physiological functions and oncogenic activities of Pim kinases.
5. Brault L, Gasser C, Bracher F, et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004-15. This review article summarizes the current knowledge about the role of Pim kinases for the pathogenesis and therapies of hematologic malignancies and solid cancers.
6. Merkel AL, Meggers E, Ocker M. PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs 2012;21:425-36
7. Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005;37:726-30 (Pubitemid 40202995)
8. Dautry F, Weil D, Yu J, Dautry-Varsat A. Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem 1988;263:17615-20
9. Lilly M, Le T, Holland P, Hendrickson SL. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene 1992;7:727-32
10. Mui AL, Wakao H, Kinoshita T, et al. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J 1996;15:2425-33 (Pubitemid 26151182)
11. Wang Z, Bhattacharya N, Weaver M, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001;2:167-79
12. Chen XP, Losman JA, Cowan S, et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 2002;99:2175-80 (Pubitemid 34169034)
13. Peltola KJ, Paukku K, Aho TL, et al. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004;103:3744-50 (Pubitemid 38596290)
14. Mizuno K, Shirogane T, Shinohara A, et al. Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun 2001;281:663-9 (Pubitemid 32917852)
15. Shay KP, Wang Z, Xing PX, et al. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 2005;3:170-81 (Pubitemid 40524900)
16. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008;27:4809-19
17. Wang Z, Bhattacharya N, Mixter PF, et al. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002;1593:45-55 (Pubitemid 35335911)
18. Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 2007;5:909-22 (Pubitemid 47416668)
19. Morishita D, Katayama R, Sekimizu K, et al. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008;68:5076-85
20. Mochizuki T, Kitanaka C, Noguchi K, et al. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999;274:18659-66
21. Bachmann M, Hennemann H, Xing PX, et al. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004;279:48319-28 (Pubitemid 39540988)
22. Bachmann M, Kosan C, Xing PX, et al. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 2006;38:430-43 (Pubitemid 41821890)
23. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007;9:932-44. This paper demonstrates that Pim1 functions as a cofactor of MYC in cell transformation, and that its activity contributes to MYC-dependent transcriptional activation and cellular transformation. (Pubitemid 47190448)
24. Fox CJ, Hammerman PS, Cinalli RM, et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003;17:1841-54 (Pubitemid 36944562)
25. Chen WW, Chan DC, Donald C, et al. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005;3:443-51 (Pubitemid 41232606)
26. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358-67 (Pubitemid 37432672)
27. Aho TL, Sandholm J, Peltola KJ, et al. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43-9 (Pubitemid 38992921)
28. Xie Y, Xu K, Linn DE, et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 2008;283:3349-56
29. Zhou XM, Liu Y, Payne G, et al. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 2000;275:25046-51 (Pubitemid 30626615)
30. Hirai I, Wang HG. Survival-factor-induced phosphorylation of bad results in its dissociation from Bcl-x (L) but not Bcl-2. Biochem J 2001;359:345-52 (Pubitemid 32999778)
31. Chao DT, Linette GP, Boise LH, et al. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995;182:821-8
32. Yang E, Zha J, Jockel J, et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91
33. Hogan C, Hutchison C, Marcar L, et al. Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem 2008;283:18012-23
34. Chiocchetti A, Gibello L, Carando A, et al. Interactions between RPS19, mutated in Diamond-Blackfan anemia, and the PIM-1 oncoprotein. Haematologica 2005;90:1453-62 (Pubitemid 41658757)
35. Iadevaia V, Caldarola S, Biondini L, et al. PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression. Oncogene 2010;29:5490-9
36. Amson R, Sigaux F, Przedborski S, et al. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989;86:8857-61 (Pubitemid 20010324)
37. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6. This paper is the first description of overexpression of Pim1 in epithelial tumors. (Pubitemid 32801464)
38. Domen J, van der Lugt NM, Laird PW, et al. Analysis of Pim-1 function in mutant mice. Leukemia 1993;7(Suppl 2):S108-12 (Pubitemid 23291133)
39. Verbeek S, van Lohuizen M, van der Valk M, et al. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991;11:1176-9 (Pubitemid 21895472)
40. Laird PW, van der Lugt NM, Clarke A, et al. In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 1993;21:4750-5. This paper describes that Pim1-deficient mice are ostensibly normal, healthy and fertile. (Pubitemid 23312750)
41. Muraski JA, Rota M, Misao Y, et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 2007;13:1467-75 (Pubitemid 350224243)
42. Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011;120:14-32
43. Hu XF, Li J, Vandervalk S, et al. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 2009;119:362-75
44. Wang J, Anderson PD, Luo W, et al. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene 2012;31:1794-803
45. Shah N, Pang B, Yeoh KG, et al. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer 2008;44:2144-51
46. Mumenthaler SM, Ng PY, Hodge A, et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 2009;8:2882-93
47. Beharry Z, Zemskova M, Mahajan S, et al. Novel benzylidene-thiazolidine- 2, 4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther 2009;8:1473-83
48. Pogacic V, Bullock AN, Fedorov O, et al. Structural analysis identifies imidazo[1, 2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007;67:6916-24. This paper is the early report on non-hinge binding of ATP-competitive Pim1 inhibitors. (Pubitemid 47105539)
49. Bullock AN, Debreczeni J, Amos AL, et al. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005;280:41675-82. This paper demonstrates the unique structure of Pim1, especially focused on the substrate binding site. (Pubitemid 43000572)
50. Jacobs MD, Black J, Futer O, et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005;280:13728-34. This paper demonstrates the unique structure of Pim1 discussing the characteristic hinge region. (Pubitemid 40517268)
51. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005;348:183-93. This paper demonstrates the unique structure of Pim1 discussing the conformational change of P-loop. (Pubitemid 40461849)
52. Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005;280:6130-7. This paper demonstrates the unique structure of Pim1, which contributes to its constitutively active conformation. (Pubitemid 40280098)
53. Cheney IW, Yan S, Appleby T, et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007;17:1679-83 (Pubitemid 46274341)
54. Holder S, Zemskova M, Zhang C, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007;6:163-72 (Pubitemid 46206679)
55. Thaimattam R, Banerjee R, Miglani R, Iqbal J. Protein kinase inhibitors: structural insights into selectivity. Curr Pharm Des 2007;13:2751-65 (Pubitemid 350130972)
56. Anastassiadis T, Deacon SW, Devarajan K, et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1039-45
57. Schenone S, Tintori C, Botta M. Using insights into Pim1 structure to design new anticancer drugs. Curr Pharm Des 2010;16:3964-78
58. Tsuganezawa K, Watanabe H, Parker L, et al. A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide. J Mol Biol 2012;417:240-52. This paper describes the rational screening of inhibitors targeting the residues of the substrate binding site.
59. Olla S, Manetti F, Crespan E, et al. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors. Bioorg Med Chem Lett 2009;19:1512-16
60. Hall MD, Salam NK, Hellawell JL, et al. Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem 2009;52:3191-204
61. Fedorov O, Marsden B, Pogacic V, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007;104:20523-8
62. Nishiguchi GA, Atallah G, Bellamacina C, et al. Discovery of novel 3, 5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett 2011;21:6366-9. This paper describes recent example of the pan-Pim kinase inhibitor for all Pim family kinases.
63. Pierre F, Stefan E, Nedellec AS, et al. 7-(4H-1, 2, 4-Triazol-3-yl) benzo[c][2, 6] naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett 2011;21:6687-92
64. Forshell LP, Li Y, Forshell TZ, et al. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget 2011;2:448-60
65. Tao ZF, Hasvold LA, Leverson JD, et al. Discovery of 3H-benzo[4, 5]thieno[3, 2-d] pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM) kinases. J Med Chem 2009;52:6621-36
66. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-15. This paper describes the phenotype of Pim1-/-, Pim2-/-and Pim3-/-mouse, and finds that Pim kinases are not required for crucial developmental processes. (Pubitemid 38787993)
67. Maksimoska J, Williams DS, Atilla-Gokcumen GE, et al. Similar biological activities of two isostructural ruthenium and osmium complexes. Chemistry 2008;14:4816-22
68. Debreczeni JE, Bullock AN, Atilla GE, et al. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl 2006;45:1580-5 (Pubitemid 44109229)
69. Bregman H, Carroll PJ, Meggers E. Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc 2006;128:877-84 (Pubitemid 43153038)
70. Feng L, Geisselbrecht Y, Blanck S, et al. Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc 2011;133:5976-86
71. Friedmann M, Nissen MS, Hoover DS, et al. Characterization of the proto-oncogene pim-1: kinase activity and substrate recognition sequence. Arch Biochem Biophys 1992;298:594-601
72. Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998;273:11987-90 (Pubitemid 28240552)
73. Kobe B, Kemp BE. Active site-directed protein regulation. Nature 1999;402:373-6 (Pubitemid 129544817)
74. Bullock AN, Debreczeni JE, Fedorov OY, et al. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM-1) kinase. J Med Chem 2005;48:7604-14 (Pubitemid 41698801)
75. Pierce AC, Jacobs M, Stuver-Moody C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J Med Chem 2008;51:1972-5 (Pubitemid 351438879)
76. Qian K, Wang L, Cywin CL, et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009;52:1814-27
77. Akue-Gedu R, Rossignol E, Azzaro S, et al. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009;52:6369-81
78. Chen LS, Redkar S, Bearss D, et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009;114:4150-7
79. Chen LS, Redkar S, Taverna P, et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011;118:693-702
80. Chang M, Kanwar N, Feng E, et al. PIM kinase inhibitors downregulate STAT3 (Tyr705) phosphorylation. Mol Cancer Ther 2010;9:2478-87
81. Siu A, Virtanen C, Jongstra J. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget 2011;2:1134-44
82. Mahalingam D, Espitia CM, Medina EC, et al. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Br J Cancer 2011;105:1563-73
83. Kelly KR, Espitia CM, Taverna P, et al. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol 2012;156:129-32
84. Hospital MA, Green AS, Lacombe C, et al. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood 2012;119:1791-2
85. Foulks JM, Xu Y, Senina A, et al. Second generation PIM inhibitor exhibits potent activity in tumor models. The 103rd Annual Meeting of the American Association for Cancer Research; March 31 - April 4 2012; Chicago, IL. Philadelphia (PA)
86. Grey R, Pierce AC, Bemis GW, et al. Structure-based design of 3-aryl-6-aminotriazolo[4, 3-b]pyridazine inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2009;19:3019-22
87. Shafer CM, Lindvall M, Bellamacina C, et al. 4-(1H-indazol-5-yl)-6- phenylpyrimidin-2 (1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett 2008;18:4482-5
88. Parker LJ, Watanabe H, Tsuganezawa K, et al. Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun 2012;68:860-6
89. Patel RY, Doerksen RJ. Protein kinase-inhibitor database: structural variability of and inhibitor interactions with the protein kinase P-loop. J Proteome Res 2010;9:4433-42
90. Guimaraes CR, Rai BK, Munchhof MJ, et al. Understanding the impact of the P-loop conformation on kinase selectivity. J Chem Inf Model 2011;51:1199-204
91. Huber K, Brault L, Fedorov O, et al. 7, 8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem 2012;55:403-13
92. Morishita D, Takami M, Yoshikawa S, et al. Cell-permeable carboxyl-terminal p27 (Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. J Biol Chem 2011;286:2681-8. This paper reports that a Pim1 substrate peptide competitively inhibited Pim1 activities in cells.
93. Palaty CK, Clark-Lewis I, Leung D, Pelech SL. Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase. Biochem Cell Biol 1997;75:153-62 (Pubitemid 127733139)
94. Wang Z, Bhattacharya N, Meyer MK, et al. Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys 2001;390:9-18 (Pubitemid 32493565)
95. Bhattacharya N, Wang Z, Davitt C, et al. Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 2002;111:80-95 (Pubitemid 36067383)
96. Peng C, Knebel A, Morrice NA, et al. Pim kinase substrate identification and specificity. J Biochem 2007;141:353-62 (Pubitemid 46770388)
97. Mikuni J, Kato M, Taruya S, et al. A fluorescence correlation spectroscopy-based assay for fragment screening of slowly inhibiting protein-peptide interaction inhibitors. Anal Biochem 2010;402:26-31
98. Nakano H, Saito N, Parker L, et al. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound. J Med Chem 2012;55:5151-64. This paper describes rational evolution of a Pim1 inhibitor targeting various residues using the data derived from the structural analysis of Pim1-inhibitor complex.